Precigen to Host a Virtual R&D Event on January 24th to Share Safety and Efficacy Data from the Phase 1 Dose Escalation and Expansion Cohorts of PRGN-2012 AdenoVerse™ Immunotherapy in Recurrent Respiratory Papillomatosis
The presentation will showcase complete clinical trial safety and efficacy data from the Phase 1 dose escalation and expansion cohorts and will be led by
"We are excited with the progress of the PRGN-2012 AdenoVerse Immunotherapy study in RRP, and are eager to showcase these safety and efficacy data, which we believe make a compelling case for the potential of PRGN-2012 to address the underserved RRP patient population and provide validation for the highly differentiated, first-in-class AdenoVerse therapeutic platform," said
Participants may register and access the live webcast through
Trademarks
Cautionary Statement Regarding Forward-Looking Statements
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties, including the possibility that the timeline for the Company's clinical trials might be impacted by the COVID-19 pandemic, and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the
Investor Contact:
Vice President, Investor Relations
Tel: +1 (301) 556-9850
investors@precigen.com
Media Contacts:
press@precigen.com
glenn.silver@finnpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/precigen-to-host-a-virtual-rd-event-on-january-24th-to-share-safety-and-efficacy-data-from-the-phase-1-dose-escalation-and-expansion-cohorts-of-prgn-2012-adenoverse-immunotherapy-in-recurrent-respiratory-papillomatosis-301713819.html
SOURCE